The fusion protein is a mimic of IL-1 antibody that blocks the free IL-1. A phase I/II biomarker trial (NCT01538719) was conducted to evaluate the efficiency against skin fibrosis of patients with dcSSc. Unfortunately, no treatment-related effect was observed including the expression of the 2G SSc gene biomarkers and the level of serum IL-6, CRP, and CCL18. This evidence concerns the gene IL6 and systemic sclerosis.